Clarkston Shares Guest Column on R&D Datasets
July 1, 2026 | Clarkston Consulting’s Lilly Saiontz recently shared a guest column with Drug Discovery Online on considerations for deciding whether to invest in R&D datasets. Read an excerpt below and the full article here.
Wondering If Your Org Should Purchase R&D Datasets?
“The life sciences industry is moving quickly toward more AI-enabled, data-driven research and development, which is changing how organizations evaluate and invest in scientific data assets.1 As advances in artificial intelligence, precision medicine, and multimodal analytics accelerate, pharmaceutical and biotech companies are increasingly prioritizing access to large-scale, high-quality data sets that combine genomic, proteomic, clinical, and real-world evidence. Increased participation in precompetitive consortia and collaborative research ecosystems is also reshaping how data is generated and shared across the industry. In this environment, competitive advantage is increasingly determined not only by access to differentiated data but also by an organization’s ability to rapidly integrate, govern, analyze, and apply these data sets to drive faster scientific insights, portfolio decisions, and therapeutic innovation.”
Also read on: cellandgene.com